Transcode Therapeutics (RNAZ) Net Equity Issued and Repurchased (2023 - 2025)
Transcode Therapeutics' (RNAZ) quarterly Net Equity Issued and Repurchased came in at $13.8 million in Q4 2025, up 95.05% YoY from $7.1 million in Q4 2024, and up 56.0% on a QoQ basis from $8.9 million in Q1 2025.
Transcode Therapeutics (RNAZ) Net Equity Issued and Repurchased (2023 - 2025) Analysis & Trends
Transcode Therapeutics (RNAZ) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $13.8 million in Q4 2025.
- Quarterly Net Equity Issued and Repurchased rose 95.05% year-over-year to $13.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.7 million (up 38.21% YoY) and the FY2025 annual result came in at $22.7 million, up 38.21% from the prior year.
- Net Equity Issued and Repurchased grew to $13.8 million in Q4 2025, from $8.9 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $13.8 million in Q4 2025 to a low of $785198.0 in Q2 2024.
- A 3-year average of $4.9 million and a median of $4.3 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 624.02% in 2024, down 89.03% in 2024.
- Tracing RNAZ's Net Equity Issued and Repurchased over 3 years: stood at $978153.0 in 2023, then jumped by 624.02% to $7.1 million in 2024, then surged by 95.05% to $13.8 million in 2025.
- The last three Net Equity Issued and Repurchased figures came in at $13.8 million (Q4 2025), $8.9 million (Q1 2025), and $7.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.81 Mn |
| Dec 31, 2025 | 13.81 Mn |
| Mar 31, 2025 | 8.85 Mn |
| Mar 31, 2025 | 8.85 Mn |
| Dec 31, 2024 | 7.08 Mn |
| Dec 31, 2024 | 7.08 Mn |
| Sep 30, 2024 | 2.45 Mn |
| Sep 30, 2024 | 2.45 Mn |
| Jun 30, 2024 | 785,198.00 |
| Jun 30, 2024 | 785,198.00 |
| Mar 31, 2024 | 6.09 Mn |
| Mar 31, 2024 | 6.09 Mn |
| Dec 31, 2023 | 978,153.00 |
| Dec 31, 2023 | 978,153.00 |
| Sep 30, 2023 | 900,000.00 |
| Sep 30, 2023 | 900,000.00 |
| Jun 30, 2023 | 7.16 Mn |
| Jun 30, 2023 | 7.16 Mn |
| Mar 31, 2023 | 1.18 Mn |
| Mar 31, 2023 | 1.18 Mn |